Hinge Health (NYSE:HNGE) Price Target Raised to $134.00

Hinge Health (NYSE:HNGE) had its target price hoisted by stock analysts at Canaccord Genuity Group from $105.00 to $134.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group‘s target price suggests a potential upside of 16.41% from the company’s previous close.

HNGE has been the topic of several other reports. Citigroup reaffirmed an “outperform” rating on shares of Hinge Health in a report on Monday, July 27th. Morgan Stanley raised their target price on shares of Hinge Health from $72.00 to $108.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $132.00 target price on shares of Hinge Health in a research note on Tuesday. Bank of America assumed coverage on shares of Hinge Health in a report on Tuesday, September 29th. They set a “buy” rating and a $110.00 price target for the company. Finally, Evercore reiterated an “outperform” rating and issued a $105.00 price target on shares of Hinge Health in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $113.53.

Hinge Health Stock Up 0.7%

Shares of HNGE stock opened at $115.11 on Tuesday. The business has a fifty day simple moving average of $98.66 and a 200 day simple moving average of $67.35. The company has a market cap of $9.29 billion, a P/E ratio of 89.93 and a beta of 1.37. Hinge Health has a twelve month low of $30.08 and a twelve month high of $118.87.

Hinge Health (NYSE:HNGE) last issued its earnings results on Monday, November 2nd. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.27 by $0.44. The firm had revenue of $234.97 million during the quarter. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%. The firm’s revenue was up 52.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) EPS. As a group, equities research analysts anticipate that Hinge Health will post 1.25 earnings per share for the current fiscal year.

Insider Buying and Selling at Hinge Health

In related news, President James Pursley sold 33,000 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $88.05, for a total value of $2,905,650.00. Following the completion of the sale, the president directly owned 706,235 shares in the company, valued at $62,183,991.75. This represents a 4.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Budge sold 55,561 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $89.45, for a total value of $4,969,931.45. Following the transaction, the chief financial officer directly owned 349,062 shares of the company’s stock, valued at approximately $31,223,595.90. This represents a 13.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,024,581 shares of company stock worth $95,632,761 over the last ninety days. Insiders own 18.92% of the company’s stock.

Institutional Investors Weigh In On Hinge Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. 11.2 Capital Management LLC acquired a new position in shares of Hinge Health in the second quarter worth approximately $204,566,531. Assenagon Asset Management S.A. boosted its holdings in Hinge Health by 2,141.9% in the third quarter. Assenagon Asset Management S.A. now owns 1,854,922 shares of the company’s stock valued at $180,373,000 after acquiring an additional 1,772,182 shares during the last quarter. Wellington Management Group LLP increased its position in Hinge Health by 169.7% during the 2nd quarter. Wellington Management Group LLP now owns 1,205,584 shares of the company’s stock valued at $100,063,000 after purchasing an additional 758,594 shares during the period. Arrowstreet Capital Limited Partnership increased its position in Hinge Health by 225.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,163,187 shares of the company’s stock valued at $44,852,000 after purchasing an additional 806,007 shares during the period. Finally, Estuary Capital Management LP bought a new position in Hinge Health during the 1st quarter worth approximately $15,201,000.

Hinge Health News Roundup

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Quarterly results exceeded consensus. Hinge Health generated approximately $235.0 million in revenue, up 52.4% year over year, and reported $0.71 in earnings per share versus estimates ranging from $0.27 to $0.63. The company also posted a 15.15% net margin, reinforcing the improving profitability story. Hinge Health reports record third quarter 2026 financial results
• Positive Sentiment: Management provided a constructive growth outlook. Hinge Health outlined 2026 revenue of $879 million to $881 million, representing another upward outlook adjustment according to coverage of the earnings call. The company also is targeting an integrated gastrointestinal care program for summer 2027, creating a potential new expansion opportunity beyond its core musculoskeletal business. Hinge Health outlines revenue outlook and GI program
• Neutral Sentiment: The earnings reaction was relatively limited. Although Hinge Health cleared published estimates and highlighted record results, reports characterized the stock’s response as muted. With a market capitalization near $9.3 billion, a price-to-earnings ratio around 89, and shares close to their one-year high, much of the strong execution may already be reflected in the valuation. Hinge Health third-quarter results beat forecasts
• Negative Sentiment: Expectations remain a key risk. Some coverage indicated that results missed the higher “whisper” forecast despite beating official consensus estimates. That gap, combined with the stock’s sharp appreciation above its 50-day and 200-day moving averages, could limit further gains unless Hinge Health continues delivering sizable revenue growth and upward guidance revisions. Hinge Health clears consensus but misses the whisper

About Hinge Health

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.